Finished
Impact of Anterior Urethral Suspension Combined With Pelvic Fascia Reconstruction During Robot-Assisted Radical Prostatectomy on Early Postoperative Urinary Continence Recovery: A Single-Center, Prospective, Single-Arm Clinical Study
NCT07725653 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated 24 July 2026
- What is being tested
- Modified RARP Combined with Anterior Urethral Suspension and Pelvic Fascia Reconstruction
- For
- Prostate Cancer
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 40 years to 80 years. About 60 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 12 Dec 2025, ends 11 July 2026. Registered 24 July 2026.
- Results
- None posted yet.
In the researchers' words
This is a single-center prospective cohort study enrolling 60 to 100 patients with prostate cancer treated at The Cancer Hospital of the Chinese Academy of Medical Sciences between December 2025 and July 2026, who will receive modified RARP combined with anterior urethral suspension and pelvic fascia reconstruction. The primary endpoint is the 3-month postoperative urinary continence recovery rate. Secondary endpoints include positive surgical margin rate, intraoperative blood loss, operative duration, postoperative complications, biochemical recurrence and other indicators. Standardized surgical procedures, standardized follow-up and multi-dimensional statistical analyses will be performed to clarify the functional benefits and oncological safety of this modified technique, so as to optimize surgical strategies for locally advanced prostate cancer.
Sites
- Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing, China
